Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

MNTA ‘ReadMeFirst’ updated:

#msg-119916806

Updates:
MNTA inks 50/50 partnership with MYL for 6 FoBs;
terms of MNTA-MYL partnership meet MNTA’s stated goals;
commentary on MNTA-MYL partnership by FierceBiotech;
why MNTA-MYL partnership does not include (infused) Avastin;

MNTA/BXLT start phase-3 trial of Humira FoB;
MNTA/BXLT report phase-1 bioequivalence data for Humira FoB;
can Abbvie block US Humira FoBs until 2022?;

2016-2017 news flow;

MNTA has strong liquidity position (including $105M expected from MYL in 2016);
3Q15 financial results and CC transcript;
former Biogen executive, Matt Ottmer, named COO;
Brean Capital has $29 price target;

patent trial on 40mg Copaxone scheduled for 9/26/15 (if not mooted by IPC);
new inference that MYL not close to FDA approval of Copaxone ANDA;

CAFC remands Lovenox patent case back to District Court for patent trial; AMPH changes its tune on Court bond;
AMPH files desperation “antitrust” lawsuit against MNTA;

MNTA resumes enrollment in phase-2 Necuparanib trial after protocol change.